Clinical and Translational Allergy最新文献

{"title":"Role of eosinophil counts in mediating the association between asthma and colon cancer","authors":"Zhi-Qing Zhan,&nbsp;Ze-Min Huang,&nbsp;Zhi-Xin Xie,&nbsp;Hao-Bin Zhou,&nbsp;Yu-Hua Luo,&nbsp;Pei-Zhen Chen,&nbsp;Tian-Ye Luo,&nbsp;Baoqing Sun,&nbsp;Zhangkai J. Cheng","doi":"10.1002/clt2.70012","DOIUrl":"10.1002/clt2.70012","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Epidemiological findings regarding the association between asthma and the risk of colon cancer (CC) are inconsistent. The causality and potential molecular mechanisms underlying asthma, eosinophil count, and CC remain unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed Mendelian randomization (MR) analysis to investigate the causality between asthma and CC and attempted to demonstrate that asthma indirectly affects CC mediated by eosinophil count through mediation analysis. Sensitivity analyses and multivariable MR were performed to test the robustness of our findings. Multiple bioinformatics tools were applied to further investigate the underlying mechanisms related to eosinophils that contribute to the pathogenesis of both asthma and CC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>MR with mediation analyses suggested that eosinophil count may play a role in the mechanism through which asthma reduces the risk of CC. Our bioinformatic analyses identified PPP1R14A as a potential therapeutic target and an eosinophil-associated biomarker for CC patients. Higher expression of PPP1R14A may be associated with a poorer prognosis in CC patients. Additionally, the lysosome pathway emerges as a shared eosinophil-related pathway in both asthma and CC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Eosinophils may contribute to a lower risk of CC in patients with asthma. PPP1R14A is a potential therapeutic target and biomarker for CC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 12","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11632118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142805611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lifetime asthma incidence is related to age at onset and allergies in western Sweden","authors":"Reshed Abohalaka,&nbsp;Selin Ercan,&nbsp;Lauri Lehtimäki,&nbsp;Linda Ekerljung,&nbsp;Helena Backman,&nbsp;Fatma Zehra Uslu,&nbsp;Saliha Selin Ozuygur Ermis,&nbsp;Madeleine Rådinger,&nbsp;Bright I. Nwaru,&nbsp;Hannu Kankaanranta","doi":"10.1002/clt2.70015","DOIUrl":"10.1002/clt2.70015","url":null,"abstract":"<p>Although asthma is more frequently diagnosed in childhood, a substantial proportion of cases manifests in adulthood. Nonetheless, few studies have comprehensively examined asthma incidence across different ages, genders, and asthma phenotypes. We conducted a retrospective evaluation of asthma incidence from birth to late adulthood, stratified by age, gender, and the presence or absence of allergies. Our analysis indicates that a significant number of asthma cases emerged in adulthood, particularly among middle-aged women, with adult-onset asthma surpassing childhood-onset asthma after the age of 35 years. Additionally, allergic asthma was more common in younger than older individuals but decreases with age, ultimately leading to a higher proportion of non-allergic asthma in older than younger individuals. These findings underscore the predominance of adult-onset asthma among females and confirm the majority of allergic asthma in children, which declines with age. Additionally, increasing age is associated with increased incidence of non-allergic asthma. Asthma heterogeneity should be considered in both clinical management and research.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 12","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11632114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"M2 macrophage derived HMOX1 defines chronic rhinosinusitis with nasal polyps","authors":"Enhao Wang,&nbsp;Yanghe Hao,&nbsp;Jing Song,&nbsp;Jing Yuan,&nbsp;Yu Hong,&nbsp;Ying Li,&nbsp;Yang Wang,&nbsp;Chengshuo Wang,&nbsp;Ming Wang,&nbsp;Luo Zhang","doi":"10.1002/clt2.70014","DOIUrl":"10.1002/clt2.70014","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Molecular signatures of chronic rhinosinusitis with nasal polyps (CRSwNP) related to macrophages remain unclear. This study aimed to develop a macrophage-associated diagnostic signature for CRSwNP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Transcriptome data from 54 patients with CRSwNP and 37 healthy controls across GSE136825, GSE36830, and GSE72713 were used to identify differentially expressed genes (DEGs) between two groups. Gene Set Enrichment Analysis and Weighted Gene Co-Expression Network Analysis pinpointed crucial pathways and gene clusters. A diagnostic model was created from these analyses and receiver operating characteristic curve (ROC), and further validated in our transcriptome data from 29 samples. Immune cell infiltration analysis was performed and linked those diagnostic genes to macrophages and verified by single-cell RNA sequencing data. Immunofluorescence co-staining of CD163 and HMOX1 was performed in nasal tissues. Mouse bone marrow-derived macrophage (BMDMs) cultures were used in functional experiments. Correlations between the expression of HMOX1 and eotaxin genes were investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>DEGs of CRSwNP versus control group were enriched in the INTERLEUKIN_4_AND_13_SIGNALING pathways. A four-gene diagnostic model (HMOX1, ALOX5, F13A1 and ITGB2) was developed and demonstrated high diagnostic precision with an area under ROC curve of 0.980 for training dataset and 0.895 for test dataset. M2 macrophage presence and HMOX1 expression significantly correlated with CRSwNP (<i>p</i> &lt; 0.001). Single-cell RNA sequencing data underscored the altered cellular composition in CRSwNP, with HMOX1 notably expressed in M2 macrophages. Immunofluorescence staining highlighted the increased infiltration of CD163+ M2 macrophages in nasal mucosa samples of eosinophilic CRSwNP, which correlated with HMOX1 protein levels (<i>p</i> &lt; 0.05). The HMOX1 inhibitor zinc protoporphyrin reduced the ratio of CD163 + HMOX1 + M2 macrophages in mouse BMDM cultures (<i>p</i> &lt; 0.05). HMOX1 expression showed a strong positive correlation with the expression of eotaxin genes (CCL11, CCL24, and CCL26; <i>p</i> &lt; 0.05 respectively).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>M2 macrophage-derived HMOX1 can be used as an innovative diagnostic signature for CRSwNP, which might be a potential regulator of eosinophilic inflammation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 12","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11624889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"10 practical priorities to prevent and manage serious allergic reactions: GA2LEN ANACare and EFA Anaphylaxis Manifesto","authors":"Antonella Muraro,&nbsp;Debra de Silva,&nbsp;Marcia Podesta,&nbsp;Aikaterini Anagnostou,&nbsp;Victoria Cardona,&nbsp;Susanne Halken,&nbsp;Pete Smith,&nbsp;Luciana Kase Tanno,&nbsp;Paul Turner,&nbsp;Margitta Worm,&nbsp;Montserrat Alvaro-Lozano,&nbsp;Stefania Arasi,&nbsp;Anna Asarnoj,&nbsp;Simona Barni,&nbsp;Kirsten Beyer,&nbsp;Lucy A. Bilaver,&nbsp;Andrew Bird,&nbsp;Roberta Bonaguro,&nbsp;Helen A. Brough,&nbsp;R. Sharon Chinthrajah,&nbsp;Emma E. Cook,&nbsp;Céline Demoulin,&nbsp;Antoine Deschildre,&nbsp;Timothy E. Dribin,&nbsp;Motohiro Ebisawa,&nbsp;Montserrat Fernandez-Rivas,&nbsp;Alessandro Fiocchi,&nbsp;David M. Fleischer,&nbsp;Eleanor Garrow,&nbsp;Jennifer Gerdts,&nbsp;Mattia Giovannini,&nbsp;Kirsi M. Järvinen,&nbsp;Mary Kelly,&nbsp;Edward F. Knol,&nbsp;Gideon Lack,&nbsp;Francesca Lazzarotto,&nbsp;Thuy-My Le,&nbsp;Stephanie Leonard,&nbsp;Jay Lieberman,&nbsp;Michael Makris,&nbsp;Lianne Mandelbaum,&nbsp;Mary Jane Marchisotto,&nbsp;Gustavo Andres Marino,&nbsp;Francesca Mori,&nbsp;Caroline Nilsson,&nbsp;Anna Nowak-Wegrzyn,&nbsp;Mikaela Odemyr,&nbsp;H. N. G. Oude Elberink,&nbsp;Kati Palosuo,&nbsp;Nandinee Patel,&nbsp;Jennifer Pier,&nbsp;Sung Poblete,&nbsp;Rima Rachid,&nbsp;Pablo Rodríguez del Río,&nbsp;Maria Said,&nbsp;Hugh A. Sampson,&nbsp;Angel Sánchez Sanz,&nbsp;Sabine Schnadt,&nbsp;Fallon Schultz,&nbsp;Alice Toniolo,&nbsp;Julia E. M. Upton,&nbsp;Carina Venter,&nbsp;Brian P. Vickery,&nbsp;Berber Vlieg-Boerstra,&nbsp;Julie Wang,&nbsp;Graham Roberts,&nbsp;Torsten Zuberbier,&nbsp;GA2LEN ANACare Centres and EFA","doi":"10.1002/clt2.70009","DOIUrl":"10.1002/clt2.70009","url":null,"abstract":"<p>This Anaphylaxis Manifesto calls on communities to prioritise 10 practical actions to improve the lives of people at risk of serious allergic reactions. The Global Allergy and Asthma European Network and the European Federation of Allergy and Airways Diseases Patients' Associations (EFA) compiled patient-centric priorities. We used qualitative consensus methods, research evidence and feedback from over 200 patient groups, stakeholder organisations and healthcare professionals. We encourage healthcare, education and food organisations to collaborate with people at risk of serious allergic reactions to tackle safety, anxiety and financial burdens for individuals and societies. Key priorities for prevention include awareness-raising campaigns for the public and professionals, school and workplace initiatives and mandatory precautionary allergen labels on food. Priorities for improving immediate and long-term management include educating healthcare professionals, patients and schools about when and how to use adrenaline, funding two approved adrenaline devices for everyone at risk, and facilitating access to allergy specialists. Integrated care pathways should include clinical and non-clinical management options such as individualised risk assessment and quality of life assessment, self-management plans, dietetic and psychosocial support and peer support. Organisations around the world are committing to work together towards these priorities.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 12","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142754886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity predicts mortality stronger in adult-onset asthma than in age- and sex-matched controls","authors":"Helena Backman,&nbsp;Caroline Stridsman,&nbsp;Anne Lindberg,&nbsp;Eva Rönmark,&nbsp;Linnea Hedman","doi":"10.1002/clt2.70011","DOIUrl":"https://doi.org/10.1002/clt2.70011","url":null,"abstract":"&lt;p&gt;To the Editor,&lt;/p&gt;&lt;p&gt;Several studies have shown that being obese is associated with an increased risk of developing asthma, especially adult-onset asthma, as well as more severe asthma symptoms.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; Obesity can affect the respiratory system in several ways. Excess body fat can mechanically lead to a decrease in lung volume, which can make breathing more difficult. Obesity is also associated with a state of chronic low-grade inflammation,&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; which can contribute to the development of asthma and exacerbate asthma symptoms.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; In addition, obesity can lead to changes in the structure and function of the airways that make them more susceptible to inflammation and cause obstruction.&lt;span&gt;&lt;sup&gt;1, 4&lt;/sup&gt;&lt;/span&gt; Obesity associates with mortality both in the general population and among adults with asthma,&lt;span&gt;&lt;sup&gt;1, 3, 5&lt;/sup&gt;&lt;/span&gt; but most studies in adults are done by stratifying population-samples by presence and absence of asthma and thus with often slightly different age and more women in those with asthma.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; Less is known about whether the obesity-mortality association is stronger in adult-onset asthma than in adults without asthma when taking age and sex into account.&lt;/p&gt;&lt;p&gt;In this hypothesis-generating study, we aimed to explore the association between obesity and mortality in patients with adult-onset asthma compared to age- and sex-matched controls.&lt;/p&gt;&lt;p&gt;During 1995–1999, 309 adults (19–61 years, 65% women) with newly onset asthma were identified in primary care and referred to the Obstructive Lung Disease in Northern Sweden (OLIN) Studies where a diagnosis of asthma and bronchial variability was confirmed.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; &lt;i&gt;N&lt;/i&gt; = 309 sex- and age-matched controls without asthma were also included. Body mass index (BMI, kg/m&lt;sup&gt;2&lt;/sup&gt;) at baseline was categorized into normal weight (BMI 20–24.9), underweight (BMI &lt; 20), overweight (BMI 25–29.9) and obesity (BMI ≥ 30). Based on the unique Swedish personal identity numbers, mortality data was linked until November 2023. Person-years were calculated as the number of years from baseline examination to death or November 2023, whichever occurred first. Means were compared across groups using &lt;i&gt;T&lt;/i&gt;-test or ANOVA, while the Chi-squared test was used to compare proportions, as appropriate. Statistical significance was set at &lt;i&gt;p&lt;/i&gt; &lt; 0.05. Cox proportional hazards regression was used to calculate hazard ratios (HR) for BMI categories (normal weight as reference) adjusted for smoking habits, age and sex, separately among cases and controls.&lt;/p&gt;&lt;p&gt;The mean age at baseline was 37 years, and there were 48% non-smokers, 31% former smokers, and 21% current smokers among the cases, compared to 53%, 22% and 25% in controls. There were more individuals with obesity in cases versus in controls (16% vs. 9%, &lt;i&gt;p&lt;/i&gt; &lt; 0.001) (Figure 1A,B). The cumulative mortality was &lt;i&gt;n&lt;/i&gt; = 27 (9%) i","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 12","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the reliability of the FricTest® 4.0 for diagnosing symptomatic dermographism","authors":"Annika Gutsche,&nbsp;Martin Metz,&nbsp;Melba Munoz,&nbsp;Kit Wong,&nbsp;Ted Omachi,&nbsp;Rui Zhao,&nbsp;Marcus Maurer,&nbsp;Vasiliki Zampeli,&nbsp;Markus Magerl","doi":"10.1002/clt2.70005","DOIUrl":"10.1002/clt2.70005","url":null,"abstract":"&lt;p&gt;To the Editor,&lt;/p&gt;&lt;p&gt;Symptomatic dermographism (SD), a common subtype of chronic inducible urticaria (CIndU), involves transient, strip-shaped wheals that itch and burn when the skin is stroked or scratched.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; SD affects ≥0.5% of the population,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; yet despite its high frequency and marked impact on quality of life, diagnostic tools and treatment options are limited.&lt;span&gt;&lt;sup&gt;1, 3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Diagnosis is based on the patient's medical history and provocation testing.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Historically, provocation testing used a smooth, blunt object to stroke the skin, but variations in individuals' disease presentation highlighted the need for validated, reproducible tools.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; The FricTest®4.0&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; is a hand-held, flat plastic comb-like tool with four smooth pins (3.0–4.5 mm long) firmly stroked along the skin. The resulting wheals determine the critical friction threshold (CFT), the shortest pin length/minimum pressure that elicits a positive wheal response.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;This study aimed to assess the reliability (reproducibility and repeatability) of FricTest inter-rater agreement (results from two different raters on the same patient at the same visit) and intra-rater agreement (results from the same rater on the same patient 7–14 days apart). Reliable results are important for monitoring treatment effects, helping patients understand triggers, and improving management. We assume that each patient's left and right forearms are the same, that visits are the same, and that previous provocation did not affect the reaction of subsequent tests.&lt;/p&gt;&lt;p&gt;This single-center study was conducted at the Urticaria Center of Reference and Excellence&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; at the Charité Hospital, Berlin, Germany. Adults had SD for &gt;6 weeks, had active SD at enrollment, and gave written informed consent. The study followed the Declaration of Helsinki principles, and the Berlin Charité Ethics Committee approved the protocol.&lt;/p&gt;&lt;p&gt;The primary endpoint, inter-rater agreement, was the intraclass correlation coefficient (ICC) between the CFT assessments of two raters within the same patient. The CFT scale is 0–4 (0 = no response, 4 = maximum response). ICCs plus upper and lower 95% confidence intervals (CI) were calculated using a mixed-effects linear model methodology.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; Rater A and B agreement was quantified using weighted kappa across four categories: left forearm, right forearm, Visit 1, and Visit 2. An ICC&lt;0.4 indicated poor reliability, and 0.6–0.8 indicated substantial reliability.&lt;/p&gt;&lt;p&gt;Two raters randomized to the order of assessments (Forearm 1 [right], Forearm 2 [left]) administered and recorded all FricTest results. At Visit 1, Rater A applied the FricTest to Forearm 1, covered the arm, and left the room. Rater B then applied the FricTest to Forearm 2, covered the arm, and left the room. Ten minutes af","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 11","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Matsumoto et al.","authors":"Molly Cremin,&nbsp;Sadhbh Hurley,&nbsp;Juan Trujillo","doi":"10.1002/clt2.70000","DOIUrl":"10.1002/clt2.70000","url":null,"abstract":"&lt;p&gt;Dear Editor,&lt;/p&gt;&lt;p&gt;We would like to respond to the recent publication by Matsumoto et al. “Milk ladder versus early oral immunotherapy in infants with cow's milk protein (CMP) allergy” which we read with interest&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; In this single center retrospective observational study the authors compared the efficacy and safety of milk ladder (ML) with early-oral immunotherapy (E-OIT) in children under the age of 2 years.&lt;/p&gt;&lt;p&gt;For over 10 years, milk ladders have been used as the mainstay of treatment for both IgE and non-IgE mediated cow’s milk protein allergy (CMPA) in Ireland. As described in this publication, the ML involves the home-based graded reintroduction of CMP containing foods in a stepwise fashion from least to most allergenic forms. This practice has been deemed safe and successful in Irish settings.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; As the use of Dietary advancement therapies (DATs) including MLs and OIT become more widespread in the global allergy community we strongly support the recollection of local data and thank the authors for publishing this paper which adds to the collective knowledge on the treatment of CMPA. This paper led us to consider our practice for patient selection and the differences between what is possible and practical in the clinical setting versus what is best practice.&lt;/p&gt;&lt;p&gt;In clinical practice the use of clinical history of parental reported immediate symptoms and proof of sensitisation is used to confirm milk allergy instead of the gold-standard Oral Food Challenge (OFC). Prior to the initiation of OIT international guidelines indicates the use of OFC to confirm the diagnosis.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; In the protocol described by Matsumoto et al. they included patients with either parent reported immediate symptoms or proof of sensitisation (Milk specific IgE &gt; 5 kUA/L). We agree with the authors that this is a limitation of the study. We feel that in the absence of a challenge proven allergy, it is likely that this cohort included children with parent reported symptoms alone (with no sensitisation or allergy) or asymptomatic sensitisation.&lt;/p&gt;&lt;p&gt;Previous studies comparing the use of OIT with total milk avoidance identified approximately half of children screened with parent reported symptoms AND evidence of sensitisation (IgE &gt; 0.35) had a negative double-blind placebo-controlled food challenge to milk.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The same limitations were discussed in research from our Irish team, we compared the use of ML and milk avoidance in real-life diagnosed CMPA patients (positive clinical history and allergy tests without OFC) and decided to label the primary outcome as reintroduction of milk instead of tolerance.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;DATs can be used in high-risk patients for the first introduction of CMP. This may be helpful when there is hesitation to introduce milk and can enable and empower families to introduce it at home in a graded way. For example, in high risk a","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 11","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GA2LEN ANACARE consensus statement: Potential of omalizumab in food allergy management","authors":"Torsten Zuberbier,&nbsp;Antonella Muraro,&nbsp;Ulugbek Nurmatov,&nbsp;Stefania Arasi,&nbsp;Katarina Stevanovic,&nbsp;Aikaterini Anagnostou,&nbsp;Roberta Bonaguro,&nbsp;Sharon Chinthrajah,&nbsp;Gideon Lack,&nbsp;Alessandro Fiocchi,&nbsp;Thuy-My Le,&nbsp;Paul Turner,&nbsp;Montserrat Alvaro Lozano,&nbsp;Elizabeth Angier,&nbsp;Simona Barni,&nbsp;Phillippe Bégin,&nbsp;Barbara Ballmer-Weber,&nbsp;Victoria Cardona,&nbsp;Carsten Bindslev-Jensen,&nbsp;Antonella Cianferoni,&nbsp;Nicolette de Jong,&nbsp;Debra de Silva,&nbsp;Antoine Deschildre,&nbsp;Audrey Dunn Galvin,&nbsp;Motohiro Ebisawa,&nbsp;David M. Fleischer,&nbsp;Jennifer Gerdts,&nbsp;Mattia Giovannini,&nbsp;Josefine Gradman,&nbsp;Susanne Halken,&nbsp;Syed Hasan Arshad,&nbsp;Ekaterina Khaleva,&nbsp;Susanne Lau,&nbsp;Richard Loh,&nbsp;Mika J. Mäkelä,&nbsp;Mary Jane Marchisotto,&nbsp;Laura Morandini,&nbsp;Charlotte G. Mortz,&nbsp;Caroline Nilsson,&nbsp;Anna Nowak-Wegrzyn,&nbsp;Marcia Podestà,&nbsp;Lars K. Poulsen,&nbsp;Graham Roberts,&nbsp;Pablo Rodríguez del Río,&nbsp;Hugh A. Sampson,&nbsp;Angel Sánchez,&nbsp;Sabine Schnadt,&nbsp;Peter K. Smith,&nbsp;Hania Szajewska,&nbsp;Natasa Teovska Mitrevska,&nbsp;Alice Toniolo,&nbsp;Carina Venter,&nbsp;Amena Warner,&nbsp;Gary W. K. Wong,&nbsp;Robert Wood,&nbsp;Margitta Worm","doi":"10.1002/clt2.70002","DOIUrl":"10.1002/clt2.70002","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Immunoglobulin E (IgE)-mediated food allergies are the most common type of food allergy, often causing rapid symptoms after exposure to allergens posing a serious health risk and a high impact on patient's and caregiver's quality of life. Omalizumab, a humanized anti-IgE monoclonal antibody, reduces allergic reactions by binding to circulating IgE. Omalizumab has been successfully used in allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, and was recently approved for treating IgE-mediated food allergies by the US Food and Drug Administration (FDA). This GA²LEN ANACARE Consensus Statement presents our position on the use of omalizumab for treating IgE-mediated food allergies, based on a systematic review and meta-analysis, experience with use for other conditions, and expert consensus achieved via an eDelphi process. Following publication of the recent OUtMATCH study (stage 1) results and subsequent FDA approval, we propose that there is now sufficient evidence to recommend omalizumab as the only drug currently available that can mechanistically reduce IgE-mediated food allergic reactions. We acknowledge that the evidence does not reach the highest level of evidence which would be needed for a guideline recommendation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 11","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infants and toddlers with sensitization to peanut are often co-sensitized to tree nuts","authors":"Lara Meixner,&nbsp;Stephanie Heller,&nbsp;Friederike Bluhme,&nbsp;Valérie Trendelenburg,&nbsp;Kirsten Beyer,&nbsp;Birgit Kalb","doi":"10.1002/clt2.70008","DOIUrl":"10.1002/clt2.70008","url":null,"abstract":"&lt;p&gt;To the Editor,&lt;/p&gt;&lt;p&gt;Especially infants with eczema are at high risk for developing food allergies and it is the current understanding that sensitization occurs via the cutaneous route due to an impaired skin barrier function.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; Accordingly, a high peanut consumption in the household has been shown to be a possible risk factor for developing peanut allergy in infancy.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Therefore, German S3-guidelines on allergy prevention recommend that peanut allergy should first be ruled out in infants with moderate to severe atopic dermatitis, before introducing peanut into the infant's diet for preventive purposes.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; During the last decades, vegan and plant-based diets have become a growing trend.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; Tree nuts, such as cashews, hazelnuts and walnuts are a nutritional mainstay of plant-based diets and plant-based alternatives for milk and milk-products often contain tree nuts.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; These changes in dietary habits may lead to a wider spread of tree nut allergens in households, increasing the risk for cutaneous exposure. There are hints, that individuals with peanut allergy have a higher likelihood of being allergic to tree nuts compared to the general population.&lt;span&gt;&lt;sup&gt;6, 7&lt;/sup&gt;&lt;/span&gt; Therefore, the aim of this study was to investigate how often peanut-sensitized infants and toddlers are sensitized to cashew, hazelnut and walnut as well as their seed storage proteins, which might be associated with a high risk for clinical reactivity.&lt;/p&gt;&lt;p&gt;The study cohort consists of infants and toddlers who were referred to the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité—Universitätsmedizin Berlin. Some of the patients underwent an oral food challenge (OFC) for routine diagnostics between 2007 and 2020. Blood as well as clinical data was collected from all patients in the frame of routine diagnostics. Inclusion criteria for the analysis of co-sensitization was age ≤2 years and specific IgE (sIgE) to peanut ≥0.1 kU/l.&lt;/p&gt;&lt;p&gt;The detection of sIgE to peanut, hazelnut, walnut and cashew and to their respective 2S albumins Ara h 2, Cor a 14, Jug r 1, Ana o 3 as well as to the 7S vicilin-like globulin Ara h 1, was performed by using the NOVEOS&lt;sup&gt;TM&lt;/sup&gt; immunoanalyzer (Garden Grove, California, USA). Sensitization was defined as sIgE ≥0.1 kU/l.&lt;/p&gt;&lt;p&gt;In order to determine the probability for a positive hazelnut food challenge by Cor a 14-sIgE and for a positive cashew food challenge by Ana o 3-sIgE for each patient, probability curves by Beyer et al. and Lange et al. were utilized.&lt;span&gt;&lt;sup&gt;8, 9&lt;/sup&gt;&lt;/span&gt; Since there is no probability curve available for walnut, the individual risk for a positive OFC with walnut could not be estimated (see Supporting Information S1 for detailed methods).&lt;/p&gt;&lt;p&gt;Sera from 101 peanut-sensitized patients (peanut-sIgE ≥0.1 kU/l) were analyzed. The median age of the patients a","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 11","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of real-world efficacy of mepolizumab on SNOT-22 outcomes in patients with unified airway disease","authors":"Ruperto González-Pérez,&nbsp;Paloma Poza-Guedes,&nbsp;María Gabriela Martín-Voso,&nbsp;Inmaculada Sánchez-Machín","doi":"10.1002/clt2.70006","DOIUrl":"10.1002/clt2.70006","url":null,"abstract":"&lt;p&gt;To the Editor,&lt;/p&gt;&lt;p&gt;The unified airway hypothesis suggests that the upper and lower airways constitute a single, interconnected organ, sharing significant physiological traits such as immunology, pathophysiology, epidemiology, and clinical features.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Allergic rhinitis (AR), various forms of chronic rhinosinusitis (CRS), including those with nasal polyposis (NP), and severe asthma (SA) share a common underlying pathogenesis known as type-2 inflammation (T2).&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; These coexisting conditions represent a substantial clinical burden and significantly impact patients' quality of life (QoL) through a variety of disruptive symptoms The SNOT-22 is a validated questionary designed to assess the symptom burden of CRS and has proven effective utility in evaluating both QoL and symptom control in AR.&lt;span&gt;&lt;sup&gt;3, 4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Mepolizumab, a monthly subcutaneous IL-5 antagonist monoclonal antibody, has been approved for treating various type 2 inflammatory conditions, including both eosinophilic SA and CRSwNP.&lt;span&gt;&lt;sup&gt;5, 6&lt;/sup&gt;&lt;/span&gt; The performance of mepolizumab on SNOT-22 scores has not been completely assessed in patients afflicted with Unified Airway Disease (UAD).&lt;/p&gt;&lt;p&gt;This Phase IV, single-center observational cohort investigation, conducted at Hospital Universitario de Canarias in Tenerife, Spain, aimed to evaluate the real-world performance of mepolizumab 100 mg every 4 weeks (100 mg-q4w) over 52-weeks on SNOT-22 scores in patients aged over 18 years with UAD, including uncontrolled SA and persistent mite (&lt;i&gt;Dermatophagoides spp&lt;/i&gt;. and/or &lt;i&gt;Blomia tropicalis&lt;/i&gt;) AR, with or without comorbid CRSwNP. Key inclusion criteria were a clinician-confirmed diagnosis of SA and AR with a T2 signature according to specific guidelines&lt;span&gt;&lt;sup&gt;7, 8&lt;/sup&gt;&lt;/span&gt; and a CRSwNP diagnosis based on EPOS criteria.&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; Pregnant and breast-feeding women were excluded. The study was approved by the local Ethical Committee of our Institution and informed consent was signed by all participants.&lt;/p&gt;&lt;p&gt;Data from clinical records collected between January 2021 and July 2024 were retrospectively analyzed, with a total of 102 patients screened. Among them, 71 patients—40 females and 31 males, median age 48 years (IQR 21)—were confirmed as eligible for the study (Table S1). Outcome data from all participants were gathered and compared at two time points: before (T0) and 52-weeks post-commencement (T1) of monthly mepolizumab. Quantitative variables were presented as median and interquartile range (IQR), whereas qualitative variables were expressed as number of observations and percentage. Individual SNOT-22 item scores were summed, and a median domain score was derived. Pulmonary function test, including pre- and post-bronchodilator spirometry (Datospir 600&lt;sup&gt;®&lt;/sup&gt;, Sibel S.A.U., Barcelona, Spain) and a validated asthma control test (ACT) were conducted in accordance with daily practice guid","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 11","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}